PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries
Authors:
- Kathleen M NeuzilKNKathleen M Neuzil
- on behalf of PATH’s Influenza Vaccine Project teamOTon behalf of PATH’s Influenza Vaccine Project team
- 1 August 2012
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 11 (8) , 939-947
Abstract
Expert Rev. Vaccines 11(8), 939-947 (2012) The 2009 influenza A/H1N1 pandemic demonstrated that a pandemic influenza virus has the potential to spread more rapidly in today's highly interconnected world than in the past. While pandemic morbidity and mortality are likely to be greatest in low-resource countries, manufacturing capacity and access to influenza vaccines predominantly exist in countries with greater resources and infrastructure. Even with recently expanded manufacturing capacity, the number of doses available within a 6-month timeframe would be inadequate to fully immunize the global population if the decision to implement a global vaccination program were made today. Improved, affordable vaccines are needed to limit the consequences of a global influenza outbreak and protect low-resource populations. PATH's Influenza Vaccine Project is supporting a range of activities in collaboration with private- and public-sector partners to advance the development of promising influenza vaccines that can be accessible and affordable for people in low-resource countries.Keywords
This publication has 35 references indexed in Scilit:
- AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in FinlandPLOS ONE, 2012
- Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 AdjuvantThe Journal of Infectious Diseases, 2012
- Antibody Breadth and Protective Efficacy Are Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle VaccinesClinical and Vaccine Immunology, 2012
- The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studiesVaccine, 2012
- Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10PLOS ONE, 2011
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control StudyPLOS Medicine, 2011
- Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 InfluenzaPLOS ONE, 2010
- Viral Etiology of Severe Pneumonia Among Kenyan Infants and ChildrenJAMA, 2010
- Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk DomainmBio, 2010
- MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly AdultsPLOS ONE, 2009